Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Oral betamimetics for maintenance therapy after threatened preterm labour|
|Citation:||The Cochrane Database of Systematic Reviews, 2012; 12(12):1-80|
|Publisher:||Update Software Ltd|
|Jodie M Dodd, Caroline A Crowther, Philippa Middleton|
|Abstract:||BACKGROUND Some women who have threatened to give birth prematurely, subsequently settle. They may then take oral tocolytic maintenance therapy to prevent preterm birth and to prolong gestation. OBJECTIVES To assess the effects of oral betamimetic maintenance therapy after threatened preterm labour for preventing preterm birth. SEARCH METHODS We updated the search of the Cochrane Pregnancy and Childbirth Group's Trials Register on 9 November 2012. SELECTION CRITERIA Randomised controlled trials comparing oral betamimetic with alternative tocolytic therapy, placebo or no therapy, for maintenance following treatment of threatened preterm labour. DATA COLLECTION AND ANALYSIS Two review authors independently applied the selection criteria and carried out data extraction and quality assessment of studies. MAIN RESULTS We did not identify any new trials from the updated search so the results remain unchanged as follows. We included 13 randomised controlled trials (RCTs) with a total of 1551 women. We found no differences for admission to the neonatal intensive care unit when betamimetics were compared with placebo (risk ratio (RR) 1.28, 95% confidence interval (CI) 0.68 to 2.41; two RCTs of terbutaline with 2600 women) or with magnesium (RR 0.80, 95% CI 0.43 to 1.46; one RCT of 137 women). The rate of preterm birth (less than 37 weeks) showed no significant difference in six RCTs, four comparing ritodrine with placebo/no treatment and two comparing terbutaline with placebo/no treatment (RR 1.11, 95% CI 0.91 to 1.35; 644 women). We observed no differences between betamimetics and placebo, no treatment or other tocolytics for perinatal mortality and morbidity outcomes. Some adverse effects such as tachycardia were more frequent in the betamimetics groups than the groups allocated to placebo, no treatment or another type of tocolytic. AUTHORS' CONCLUSIONS Available evidence does not support the use of oral betamimetics for maintenance therapy after threatened preterm labour.|
|Keywords:||Humans; Magnesium Compounds; Terbutaline; Ritodrine; Indomethacin; Tocolytic Agents; Administration, Oral; Pregnancy; Female; Obstetric Labor, Premature; Randomized Controlled Trials as Topic; Adrenergic beta-2 Receptor Agonists; Maintenance Chemotherapy|
|Rights:||Copyright © 2012 The Cochrane Collaboration.|
|Appears in Collections:||Obstetrics and Gynaecology publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.